Uptal Dinesh Patel
Adjunct Professor in the Department of Medicine
Affiliate, Duke Global Health Institute
Appointment:
Topics:
Uptal Dinesh Patel
Adjunct Professor in the Department of Medicine
Affiliate, Duke Global Health Institute
Uptal Patel, MD is an Adjunct Professor interested in population health with a broad range of clinical and research experience. As an adult and pediatric nephrologist with training in health services and epidemiology, his work seeks to improve population health for patients with kidney diseases through improvements in prevention, diagnosis and treatment.
Prior efforts focused on four inter-related areas that are essential to improving kidney health: i) reducing the progression of chronic kidney disease by improving its detection and management, particularly by leveraging technology to facilitate engagement and self-management; ii) elucidating the inter-relationships between kidney disease and cardiovascular disease, which together amplify the risk of death; iii) improving the evidence in nephrology through comparative effectiveness research, including clinical trials, observational studies, and meta-analyses; and iv) promoting more optimal clinical health policy for all patients with kidney disease. These inter-disciplinary projects have been funded by a variety of public and private sources including the Robert Wood Johnson Foundation, Veterans Affairs, National Institutes of Health, Agency for Healthcare Research & Quality, Food and Drug Administration, Centers for Medicare & Medicaid Services, Renal Physicians Association, and the American Society of Nephrology.
Current efforts seek to provide novel therapies for kidney diseases through a clinical development program that he leads at Gilead Sciences.
Publications
-
Lombardi Y, Raynaud M, Schatzl M, Mayer KA, Diebold M, Patel UD, et al. Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system. Am J Transplant. 2025 May;25(5):1130–2.Diebold M, Gauthier PT, Mayer KA, Mackova M, Hinze C, Chang J, et al. Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies. Nat Med. 2025 May;31(5):1668–76.Heerspink HJL, Perkovic V, Tuttle KR, Pergola PE, Mahaffey KW, Patel UD, et al. Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial. J Am Soc Nephrol. 2024 Dec 1;35(12):1726–36.Bosworth HB, Patel UD, Lewinski AA, Davenport CA, Pendergast J, Oakes M, et al. Clinical Outcomes Among High-Risk Primary Care Patients With Diabetic Kidney Disease: Methodological Challenges and Results From the STOP-DKD Study. Med Care. 2024 Oct 1;62(10):660–6.
See more publications at Scholars@Duke